论文部分内容阅读
目的观察和评价微卡联合常规化疗药物治疗新涂阳肺结核的疗效。方法 302例新涂阳肺结核患者被随机分为治疗组和对照组,每组各151例,治疗组给予2HRZE/4H3R3加用微卡菌苗治疗6个月,对照组只用2HRZE/4H3R3治疗6个月,观察治疗后肺部病灶吸收率、痰菌阴转率、微卡治疗不良反应情况。结果治疗2、4、6月末时,治疗组病灶吸收率明显高于对照组,差异均有统计学意义(P<0.05)。治疗组和对照组2、3、5、6月末时,治疗组痰菌转阴率明显高于对照组,差异均有统计学意义(P<0.05)。接受微卡治疗无严重不良反应。结论微卡联合常规化疗药物治疗新涂阳肺结核病人可显著增强常规化疗效果,有助于病灶吸收好转、痰菌转阴,且有较好的安全性,可作为新涂阳肺结核的辅助治疗。
Objective To observe and evaluate the efficacy of micro-card combined with conventional chemotherapeutic drugs in the treatment of new smear-positive pulmonary tuberculosis. Methods 302 cases of new smear-positive pulmonary tuberculosis patients were randomly divided into treatment group and control group, 151 cases in each group. The treatment group received 2HRZE / 4H3R3 plus Mika vaccine for 6 months while the control group received only 2HRZE / 4H3R3 6 Month, observe the absorption rate of lung lesions after treatment, sputum negative conversion rate, the adverse reactions of micro-card treatment. Results At the end of 2, 4 and 6 months, the absorption rate of lesions in treatment group was significantly higher than that in control group (P <0.05). At the end of two, three, five and six months in the treatment group and the control group, the negative rate of sputum in the treatment group was significantly higher than that in the control group (P <0.05). Micro-card treatment without serious adverse reactions. Conclusions The combination of micro-card and conventional chemotherapeutic drugs in the treatment of newly smear-positive pulmonary tuberculosis patients can significantly enhance the effect of conventional chemotherapy, which can help to improve the absorption of the lesion, turn the sputum negative and have better safety, and can be used as adjuvant therapy for new smear-positive pulmonary tuberculosis.